S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Molten lava on Hawaii's Big Island could block main highway
Thousands protest in South Korea in support of truckers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Molten lava on Hawaii's Big Island could block main highway
Thousands protest in South Korea in support of truckers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Molten lava on Hawaii's Big Island could block main highway
Thousands protest in South Korea in support of truckers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Estonia to buy US rocket artillery system in $200M deal
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Molten lava on Hawaii's Big Island could block main highway
Thousands protest in South Korea in support of truckers
OTCMKTS:BICX

BioCorRx - BICX Stock Forecast, Price & News

$1.85
0.00 (0.00%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.85
▼
$1.85
50-Day Range
$1.16
▼
$2.69
52-Week Range
$1.00
▼
$5.00
Volume
N/A
Average Volume
443 shs
Market Capitalization
$14.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BICX stock logo

About BioCorRx (OTCMKTS:BICX) Stock

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

Receive BICX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCorRx and its competitors with MarketBeat's FREE daily newsletter.

BICX Stock News Headlines

November 22, 2022 | finance.yahoo.com
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.
November 15, 2022 | finanznachrichten.de
BioCorRx Inc: BioCorRx Provides Business Update for the Third Quarter of 2022
November 15, 2022 | finance.yahoo.com
BioCorRx Provides Business Update for the Third Quarter of 2022
October 24, 2022 | finance.yahoo.com
BioCorRx to Present at the LD Micro Main Event XV on October 25th
October 20, 2022 | finance.yahoo.com
BioCorRx to Participate at the LD Micro Main Event XV
October 13, 2022 | finance.yahoo.com
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
September 29, 2022 | nz.finance.yahoo.com
2B3D Shares Addiction Treatment Deliverables from BioCorRx for Phase I of Mental Health Metaverse Platform Beta
September 16, 2022 | finance.yahoo.com
BICX: Pivotal trial underway
September 6, 2022 | apnews.com
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 4, 2022 | reuters.com
BICX.PK - Biocorrx Inc | Stock Price & Latest News | Reuters
August 16, 2022 | finance.yahoo.com
BioCorRx Provides Business Update for the Second Quarter of 2022
July 13, 2022 | finance.yahoo.com
BioCorRx to Participate in the Benzinga All Access Event on July 15th
July 6, 2022 | finance.yahoo.com
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast
June 30, 2022 | finance.yahoo.com
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
June 17, 2022 | finance.yahoo.com
BioCorRx Featured on LiveNOW from FOX
May 31, 2022 | finance.yahoo.com
BioCorRx to Present at the LD Micro Invitational XII on June 7th
May 19, 2022 | finance.yahoo.com
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
May 17, 2022 | finance.yahoo.com
BioCorRx Business Update for the First Quarter of 2022
April 27, 2022 | seekingalpha.com
BioCorRx starts recruiting in trial of biodegradable naltrexone pellet BICX104 for opioid disorder
April 26, 2022 | finanznachrichten.de
BioCorRx Inc.: BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th
April 26, 2022 | finance.yahoo.com
BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th
April 19, 2022 | finance.yahoo.com
BioCorRX Inc. Discusses FDA Approval Process for Implantable Naltrexone Pellet, BICX104, with The Stock Day Podcast
April 11, 2022 | finance.yahoo.com
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
April 1, 2022 | finance.yahoo.com
BioCorRx Provides 2021 Year-End Business Update
March 24, 2022 | nz.finance.yahoo.com
Echodyne CTO to Present at the 2022 IEEE Radar Conference
See More Headlines
Receive BICX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCorRx and its competitors with MarketBeat's FREE daily newsletter.

BICX Company Calendar

Last Earnings
11/17/2016
Today
12/04/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Specialty outpatient clinics, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BICX
CUSIP
N/A
CIK
1443863
Web
www.biocorrx.com
Phone
(714) 462-4880
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,210,000.00
Net Margins
-3,089.66%
Pretax Margin
-3,045.52%
Return on Equity
N/A
Return on Assets
-487.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.07
Quick Ratio
0.07

Sales & Book Value

Annual Sales
$50,000.00
Price / Sales
283.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.94) per share
Price / Book
-1.97

Miscellaneous

Outstanding Shares
7,660,000
Free Float
6,022,000
Market Cap
$14.17 million
Optionable
Not Optionable
Beta
0.74

Key Executives

  • Ms. Lourdes Felix (Age 54)
    CEO, CFO & Director
    Comp: $250k
  • Mr. Brady James Granier (Age 50)
    Pres & Director
    Comp: $275k
  • Mr. Thomas Patrick Welch (Age 50)
    Exec. VP
    Comp: $165k
  • Dr. George N. Fallieras
    Medical Consultant

Key Competitors

View All Competitors













BICX Stock - Frequently Asked Questions

How have BICX shares performed in 2022?

BioCorRx's stock was trading at $4.33 at the start of the year. Since then, BICX shares have decreased by 57.3% and is now trading at $1.85.
View the best growth stocks for 2022 here.

How were BioCorRx's earnings last quarter?

BioCorRx Inc. (OTCMKTS:BICX) posted its quarterly earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.17 million for the quarter.

What other stocks do shareholders of BioCorRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCorRx investors own include Mondi (MNDI), Alkermes (ALKS), Editas Medicine (EDIT), ImmunoGen (IMGN), Intel (INTC), Netflix (NFLX), Nektar Therapeutics (NKTR), Oracle (ORCL), SS&C Technologies (SSNC) and AT&T (T).

What is BioCorRx's stock symbol?

BioCorRx trades on the OTCMKTS under the ticker symbol "BICX."

How do I buy shares of BioCorRx?

Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCorRx's stock price today?

One share of BICX stock can currently be purchased for approximately $1.85.

How much money does BioCorRx make?

BioCorRx (OTCMKTS:BICX) has a market capitalization of $14.17 million and generates $50,000.00 in revenue each year. The company earns $-5,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How can I contact BioCorRx?

BioCorRx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The official website for the company is www.biocorrx.com. The company can be reached via phone at (714) 462-4880 or via email at investors@biocorrx.com.

This page (OTCMKTS:BICX) was last updated on 12/4/2022 by MarketBeat.com Staff